Best Life Sciences Companies in Basel, Switzerland
The 106 best Life Sciences companies in Basel, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Windward Bio.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Basel
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Windward Bio Company develops monoclonal antibody therapeutics for immunological and respiratory diseases | $365M | 1 mo ago | — | Luca Santarelli Founder | — | — |
| 2 | Syngenta Developer of technologies and sustainable farming practices for farmers | $250M | 37 mo ago | 501 | Jon Fyrwald CEO | 1,334 patents Genetically engineered crops: haploid induction, flowering control, and disease resistance traits. | — |
| 3 | Bright Peak Therapeutics Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease | $232M | 25 mo ago | 57 | Jeffrey Bode Co-Founder | 91 patents Engineered cytokine immunocytokines for targeted immune activation in oncology | — |
| 4 | Alentis Therapeutics Developer of therapies for treating fibrosis, cirrhosis, and liver cancer | $184M | 19 mo ago | 38 | Thomas Baumert Founder & Board Member | 35 patents Bispecific anti‑Claudin‑1/EGFR antibodies for cancer, liver disease and fibrosis therapy | — |
| 5 | Nouscom Developer of viral-vector-based vaccines for the treatment of cancer | $152M | 27 mo ago | 37 | — | 129 patents Personalized and universal cancer vaccines using neoantigens and viral vector immunotherapies | — |
| 6 | VectivBio Developer of transformative therapeutics for rare diseases | $145M | 47 mo ago | 42 | — | 35 patents GLP‑2 peptide analogs and formulations for treating graft‑versus‑host disease | — |
| 7 | CRISPR Therapeutics Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 30 mo ago | 458 | — | 912 patents CRISPR genome editing for engineered universal donor cells and cancer immunotherapy | — |
| 8 | Speedel Develops renin inhibitors for the treatment of cardiovascular and metabolic diseases | $100M | 233 mo ago | 40 | Andrin Oswald CEO | — | — |
| 9 | Granite Bio Developer of therapeutic antibodies that target inflammatory, autoimmune, and fibrotic conditions | $100M | 13 mo ago | — | Matthias Mack Founder | — | — |
| 10 | Nuclidium Developer of radiopharmaceuticals for the treatment of cancer | $99M | 0 mo ago | 8 | Leila Jaafar Founder & CEO | 41 patents Targeted radiopharmaceuticals for FAP and integrin imaging/therapy using high-purity radionuclides | — |
| 11 | RhyGaze Developer of gene therapies to restore vision | $97M | 17 mo ago | — | Charles Gubser Co-Founder | — | — |
| 12 | Synosia Therapeutics Developer of therapeutics for the treatment of CNS disorders | $91M | 188 mo ago | 17 | — | — | — |
| 13 | Mosanna Therapeutics Developer of small molecule therapeutics for sleep apnea | $80M | 12 mo ago | 4 | Jonathan Talbot Co-Founder & CEO | — | — |
| 14 | NBE-Therapeutics Developer of antibody-drug conjugates for cancer | $66M | 77 mo ago | 21 | — | 154 patents Site-specific antibody‑drug conjugate technologies using anthracycline payloads | 1 job opening |
| 15 | Bioversys Developer of therapeutics for Antimicrobial Resistance | $62M | 41 mo ago | 24 | Marc Gitzinger Founder & CEO | 233 patents Rifabutin antibiotic analogs and lyophilized formulations for anti‑tuberculosis therapy | — |
| 16 | PIQUR Developer of anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition | $60M | 131 mo ago | 9 | — | — | — |
| 17 | Cellestia Developer of small molecule cancer therapeutics targeting NOTCH pathway | $48M | 58 mo ago | 19 | — | — | — |
| 18 | T3 Pharma Developer of novel and innovative medicines to treat cancer | $43M | 71 mo ago | 18 | — | 245 patents Novel small‑molecule immunomodulators and anti‑angiogenic agents for inflammatory and oncologic therapies | — |
| 19 | Polyneuron Developer of antibody catch technology for treatment antibody-mediated autoimmune diseases | $40M | 62 mo ago | 9 | — | — | — |
| 20 | NimbleGen NGS solutions for research applications | $31M | 227 mo ago | 135 | Rebecca Selzer ex-President & CEO | — | — |
| 21 | Vector BioPharma Developer of gene delivery platform to treat various disease conditions | $30M | 46 mo ago | 39 | Lorenz Mayr Co-Founder | 7 patents Targeted adenoviral gene‑delivery platforms for immune‑cell therapies and vector production | — |
| 22 | Aurealis Therapeutics Developer of cell and gene therapies for chronic wounds and cancer | $22M | 19 mo ago | 17 | — | 10 patents Inducible bacterial expression platforms for therapeutic protein production | 1 job opening |
| 23 | Lumavita Developer of small molecule therapeutics for gynecological infections | $22M | 204 mo ago | — | Cees Winnips Co-Founder & CSO | 22 patents High-purity pentamycin antibiotic purification and formulation processes | — |
| 24 | 4-Antibody Antibody discovery and optimization platform for drug development | $21M | 233 mo ago | 42 | — | 8 patents Antibody and binding protein discovery/engineering using nucleic acid sequencing and modified lymphocytes | — |
| 25 | TargImmune Therapeutics Developer of drugs for treating cancer | $19M | 59 mo ago | 21 | Esteban Villar CEO | 99 patents Polymer‑based targeted nucleic‑acid delivery systems for cancer immunotherapy | — |
| 26 | Ziemer Ophthalmology Portfolio of devices for refractive and corneal surgery | $17M | — | 220 | — | — | — |
| 27 | Engimmune Therapeutics Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases | $16M | 49 mo ago | 25 | Sai Reddy Co-Founder | — | — |
| 28 | Resistell Provider of antibiotic susceptibility testing | $13M | 42 mo ago | 31 | — | 8 patents Micro/nano particle motion analysis and bio‑functionalized cantilever sensing technologies. | — |
| 29 | Strekin Developer of drugs for the treatment of hearing loss | $13M | 81 mo ago | — | Alexander Bausch Co-Founder & CEO | 13 patents Ophthalmic disease treatments and oral extended‑release drugs for hearing loss prevention | — |
| 30 | Aurealis Pharma Developer of treatments for inflammatory diseases | $13M | 60 mo ago | — | Thomas Wirth Co-Founder & Chairman | — | — |
| 31 | TECregen Developer of ligand-based solutions to restore and preserve thymus function | $13M | 5 mo ago | — | Ignacio Moraga Co-Founder & Chief Scientific Officer | — | — |
| 32 | FoRx Therapeutics Developer of compounds for treating cancer | $11M | 6 mo ago | 22 | Sotirios Sotiriou Co-Founder | 35 patents Small-molecule inhibitors of PARG and WRN enzymes for cancer therapeutics | — |
| 33 | Artidis Provider of nanotechnology tool for cancer diagnosis | $9M | 78 mo ago | 4 | Marija Plodinec Co-Founder & Chief Executive Officer | 21 patents Nanomechanical tissue analysis via atomic force microscopy for cancer diagnostic and treatment prediction | — |
| 34 | Vaximm Developing active immunotherapies (vaccines) for patients suffering from cancer. | $8M | 185 mo ago | 7 | — | 148 patents VEGFR-2‑targeted DNA vaccine platforms for cancer immunotherapy | — |
| 35 | Naviswiss Provider of miniaturized surgical navigation and measurement systems | $6M | 77 mo ago | 11 | Bruno Knobel Co-Founder | 26 patents Orthopedic surgical navigation tools and sterile optical device accessories for bone procedures | 3 launchs |
| 36 | Curatis AG Swiss specialty Pharma company focussed on rare diseases and specialty care | $5M | 1 mo ago | — | Gunter Graubach Founder | 7 patents Repurposed pharmaceutical agents for migraine and medication‑overuse headache treatment | — |
| 37 | MaxWell Biosystems Developer of an in vitro assay platform based on electrophysiology | $5M | 60 mo ago | 40 | — | — | — |
| 38 | RocketVax Developer of therapeutic solutions for the treatment of SARS-CoV-2 | $4M | 40 mo ago | 6 | — | 24 patents Attenuated SARS‑CoV‑2 viral vectors and synthetic long‑chain nucleic acids for coronavirus vaccines | — |
| 39 | Allegria Therapeutics Developer of therapeutics for allergy and inflammatory diseases | $4M | 6 mo ago | — | Maria Van Dongen Chief Executive Officer & Co-founder | — | — |
| 40 | Mysthera Therapeutics Developer of therapuetics for auto-immune diseases | $4M | 34 mo ago | — | Marta Marti Co-Founder | — | — |
| 41 | Mininavident A miniaturised navigation system for dental implant | $1M | 55 mo ago | 7 | Frank Berlinghoff Co-Founder | 17 patents Patents concentrated in health & consumer products | — |
| 42 | Bottmedical Provider of smart devices to manage sleep apnea | $1M | 42 mo ago | 13 | Jeannette von Jackowski Co-Founder | 17 patents Dental appliance fabrication, bio‑based orthodontics, and intra‑oral drug delivery solutions | — |
| 43 | FimmCyte Developer of therapeutics to treat endometriosis | $1M | 27 mo ago | 4 | Valentina Vongrad Co-Founder | — | — |
| 44 | Inofea Developing a nanoparticle platform technology to stabilize enzymes | $478K | 60 mo ago | 9 | — | 35 patents Enzymatic biocatalysis platforms for producing antibody‑drug and immunoligand conjugates | — |
| 45 | Translation-X Developer of therapeutics to treat Autism Spectrum Disorders | $177K | 20 mo ago | — | Ozgur Genc Founder | — | — |
| 46 | NXI Therapeutics Developer of immunotherapies for autoimmune diseases and organ transplantation | $159K | 48 mo ago | 4 | Rajesh Jayachandran Co-Founder | — | — |
| 47 | BioCopy Developer of immunotherapies for tumor and autoimmune diseases | $116K | 92 mo ago | 27 | Niko Bausch Co-Founder | — | — |
| 48 | Pattern Biosciences Developer of programmable gene therapies for cancer treatment | $114K | 83 mo ago | 8 | Bartolomeo Angelici VP Discovery Research | — | — |
| 49 | Metys Pharmaceuticals Developer of drugs for chemotherapy-induced peripheral neuropathy | $113K | 85 mo ago | 10 | Michael Scherz Founder & CEO | 69 patents Enantiomerically enriched neuroactive small molecules for CNS therapeutics | — |
| 50 | Stratpharma Developing skin therapeutics using a patented polymer based drug delivery technology | $111K | 75 mo ago | 113 | — | — | — |
Top 12 Life Sciences companies in Basel
#1
Series B · Basel, Basel Stadt · founded 2020$365Mraised▾
Company develops monoclonal antibody therapeutics for immunological and respiratory diseases. It focuses on advancing a thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development. It also creates novel, long-acting bispecific programs for immunological diseases. The company's lead candidate, WIN378, is a fully human monoclonal antibody engineered for extended half-life and effector silencing, targeting the TSLP ligand to treat asthma, COPD, and other inflammatory phenotypes.
- May 2026Series B$165M
- Jan 2025Series A$200M
#2
Series B · Basel, Basel Stadt · founded 2017 · 8 employees$99Mraised▾
Developer of radiopharmaceuticals for the treatment of cancer. The company is developing copper-based therapeutics and companion diagnostics which include NuriPro for Prostate cancer, TraceNET for Neuroendocrine tumors (NET), and CuNeo for Colorectal, Gastric & lobular breast cancer.
- Jul 2025Series B$99M
#3
Public · Basel, Basel Stadt · founded 2002$5.3Mraised▾
Curatis AG is a developer of therapeutics for rare diseases. The products developed are antitoxins (cyanide and digoxin) for chorea associated with Huntington's disease and interstitial cystitis. The product pipeline includes products in phase II (episodic headaches, and migraines with aura) and one in preclinical for WABB (Wolfram syndrome, Alström syndrome, Bardet-Biedl syndrome).
- May 2026Post IPO$3.8M
- Nov 2025Post IPO$1.5M
#4
Seed · Basel, Basel Stadt · founded 2023$12.6Mraised▾
Developer of ligand-based solutions to restore and preserve thymus function. The company engineers solutions to regenerate the thymus’s natural ability to create and maintain a functional immune system. It focuses on enhancing immune resilience and improving infection resistance. The company also accelerates recovery for patients with thymus-related disorders.
- Jan 2026Seed$12.6M
#5
Series A · Basel, Basel Stadt · founded 2022 · 4 employees$80Mraised▾
Developer of small molecule therapeutics for sleep apnea. It offers a lead candidate MOS-118 a targeted precision medicine that is based on the cardiometabolic impact on obstructive sleep apnea.
- Jun 2025Series A$80M
- Apr 2023Seed—
- Jul 2022Seed—
#6
Series B · Basel, Basel Stadt · founded 2021$100Mraised▾
Developer of therapeutic antibodies that target inflammatory, autoimmune, and fibrotic conditions. The pipeline consist of GRT-001 for depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP and GRT-002 has proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.
- Apr 2025Series A$30M
- Apr 2025Series B$70M
#7
Series A · Basel, Basel Stadt · founded 2019 · 22 employees$10.8Mraised▾
FORx Therapeutics develops compounds for treating cancer. The compounds work against targets involved in the repair of collapsed DNA replication forks. The company is developing small chemical inhibitors of the DNA repair pathways to specifically target cancer cells while sparing normal cells.
- Dec 2025Series A$50M
- Jun 2024Series A—
- Apr 2020Seed$10.8M
#8
Series D · Basel, Basel Stadt · founded 2019 · 38 employees$184.3Mraised▾
Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.
- Nov 2024Series D$181.4M
- Apr 2023Series C$105M
- Jun 2021Series B$67M
- Apr 2019Series A$12.3M
#9
Series A · Basel, Basel City · founded 2024$97.2Mraised▾
Developer of gene therapies to restore vision. It offers gene therapy technology that delivers a light-sensor gene specifically to cone cells to improve vision in patients suffering from retinal diseases causing blindness
- Jan 2025Series A$86M
- Jul 2024Seed$11.2M
#10
Seed · Basel, Basel Stadt · founded 2023$3.5Mraised▾
Developer of therapeutics for allergy and inflammatory diseases. The company is working on RNA processing and the discovery of peptide-based therapeutics for cell-mediated diseases such as allergy and inflammatory conditions.
- Dec 2025Seed$5.1M
- May 2024Seed$3.5M
#11
Series C · Basel, Basel Stadt · founded 2017 · 57 employees$232Mraised▾
Developer of small molecule-based therapeutic solutions for the treatment of cancer and autoimmune disease. The company is involved in the development of cytokines by using Enhanced Design and Combine (EDC) platform for immuno-oncology indications.
- May 2024Series C$90M
- Mar 2021Series B$107M
- Jul 2020Series A$35M
#12
Series B · Basel, Basel Stadt · founded 2010 · 17 employees$22Mraised▾
Developer of cell and gene therapies for chronic wounds and cancer. The company focuses on creating therapies for unmet medical needs. Its multi-target cell and gene therapy platform addresses complex multi-factorial diseases. The company generates pre-clinical, clinical, and health-economic evidence.
- Nov 2024Series B$9M
- 2021Series A—
- Aug 2017Series A$5.8M
- Jan 2016Seed$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Basel is moving
A read on the academic research around Biotechnology in Basel — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 44 papers.
Basel's University of Basel and University Hospital lead RNA splicing, viral immunology, and gene delivery research across 44 papers, with a cautiously optimistic stance (0.27) balancing breakthroughs against genuine concerns.
- University of Basel30
- University Hospital of Basel9
- Department of Biomedicine Basel5
- Institute of Molecular and Clinical Ophthalmology Basel4
- Allgemeine Gewerbeschule Basel3
- Polysome2
- Autoantibody1
- Glycoconjugate1
- Epitope1
- Immune system1
- Streptococcus mutans2
- Bacteria2
- Raw material2
- Streptococcaceae2
- Electrochemiluminescence1
- Pesticide3
- Human health2
- Cannabis2
- Index (typography)2
- Bed nets2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.